Zymergen, Inc. (ZY)

NASDAQ: ZY · IEX Real-Time Price · USD
2.53
-0.34 (-11.85%)
Aug 19, 2022 4:00 PM EDT - Market closed
-11.85%
Market Cap 263.37M
Revenue (ttm) 14.58M
Net Income (ttm) -364.92M
Shares Out 104.10M
EPS (ttm) -3.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 778,368
Open 2.82
Previous Close 2.87
Day's Range 2.49 - 2.85
52-Week Range 1.10 - 14.68
Beta n/a
Analysts Sell
Price Target 2.35 (-7.1%)
Earnings Date Aug 15, 2022

About ZY

Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. [Read more...]

Industry Specialty Chemicals
IPO Date Apr 22, 2021
CEO Joshua Hoffman
Employees 502
Stock Exchange NASDAQ
Ticker Symbol ZY
Full Company Profile

Financial Performance

In 2021, Zymergen's revenue was $16.74 million, an increase of 26.04% compared to the previous year's $13.28 million. Losses were -$361.79 million, 38.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ZY stock is "Sell." The 12-month stock price forecast is 2.35, which is a decrease of -7.11% from the latest price.

Price Target
$2.35
(-7.11% downside)
Analyst Consensus: Sell
Stock Forecasts

News

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ

NEW YORK , Aug. 11, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches o...

Other symbols: GMTXLOTZMANT

Investor Alert - The M&A Class Action Firm Announces the Investigation of Zymergen Inc. - ZY

NEW YORK , July 27, 2022 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rat...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates IEA, ZY, FLAC

NEW YORK , July 26, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches o...

Other symbols: IEA

SHAREHOLDER ALERT: Weiss Law Investigates Infrastructure and Zymergen Inc.

NEW YORK , July 25, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zymergen Inc. ("Zymergen" or the "Company...

Other symbols: DNA

ZYMERGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of ...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zymergen Inc. (Nas...

Other symbols: DNA

Cathie Wood Loaded Up on Zymergen (ZY) Stock Before Ginkgo Buyout

Zymergen shares are rallying after an all-stock buyout from Ginkgo Bioworks. Cathie Wood's Ark owns both DNA shares and ZY stock.

Zymergen (ZY) Stock Soars 20% on Acquisition News

Zymergen finally received some much-needed good news when Ginkgo Bioworks agreed to buy out the firm, sending ZY stock soaring. The post Zymergen (ZY) Stock Soars 20% on Acquisition News appeared first ...

Shareholder Alert: Ademi LLP investigates whether Zymergen Inc. has obtained a Fair Price in its transaction with Ginkgo

MILWAUKEE , July 25, 2022 /PRNewswire/ -- Ademi LLP is investigating Zymergen (NASDAQ: ZY) for possible breaches of fiduciary duty and other violations of law in its transaction with Ginkgo.  Click here...

Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million

The deal values Zymergen at a fraction of its $3 billion valuation at Zymergen's IPO last April.

Other symbols: DNA

ZY Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Zymergen Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Zymergen Inc. (NASDAQ: ZY) to Ginkgo Bioworks for 0.9179 Ginkgo shares for each Zymergen sh...

Ginkgo to Acquire Zymergen

Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's complementary automation, software, and data science t...

Other symbols: DNA

Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

Octant doubles its initial investment in Zymergen's Automation Technology to significantly increase the scale and throughput of its drug discovery platform Octant doubles its initial investment in Zymer...

Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New Polyimide for Use in High-Performance 3D Printi...

EMERYVILLE, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use i...

Zymergen Sells Modular Automation System to Octant to Scale Next-Generation Drug Discovery Platform

EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation system...

Zymergen (ZY) Reports Q1 Loss, Tops Revenue Estimates

Zymergen (ZY) delivered earnings and revenue surprises of 1.41% and 57.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zymergen Reports Preliminary First Quarter 2022 Financial Results

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the first quarter ended March 31,...

Zymergen (ZY) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zymergen (ZY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zymergen to Participate in the BofA Securities 2022 Healthcare Conference

EMERYVILLE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced the company will be participating in the upcoming BofA Securities 2022 Healthcare Conf...

Why Shares of Zymergen Are Plunging Today

This growth stock is experiencing serious volatility -- which shouldn't be all that surprising after all.

Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022

EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it will report preliminary financial results for the first quarter 2022 after market cl...

Zymergen Reports Preliminary Fourth Quarter and Full Year 2021 Financial Results

EMERYVILLE, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the fourth quarter and full yea...

Zymergen to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on March 22nd, 2022

EMERYVILLE, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it will report preliminary financial results for the fourth quarter and full year 2021 ...

Zymergen Advances Molecules for Prominent Malaria and COVID-19 Drug Targets for Further Testing

EMERYVILLE, Calif., March 06, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen (ZY) is pleased to announce early results from its work on infectious disease, discovering hundreds of potential nov...

Zymergen to Present at the 42nd Annual Cowen Healthcare Conference

EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced the company will be participating in the upcoming 42nd Annual Cowen Virtual Healthcare ...

Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morgan Healthcare Conference

Delivering platform expertise and developing novel microbes, molecules and materials for customers across a variety of markets Delivering platform expertise and developing novel microbes, molecules and ...